| The interaction between SPARC and integrin beta1 results in suppression of cell proliferation in prostate cancer. | prostate, |
| SPARC expression was inversely associated with the degree of malignancy and it had a negative correlation with VEGF-C and VEGF-D expression. Results suggest SPARC might function as a tumor suppressor inhibiting angiogenesis and lymphangiogenesis in ovarian cancer by reducing the expression of VEGF-C and VEGF-D. | ovarian, |
| SPARC is down-regulated by DNA methylation and functions as a tumor suppressor in T-cell lymphoma | lymphoma, |
| many of the genes within the CDR associated with the 5q- syndrome exhibit significantly decreased expression and that SPARC, as a potential tumor suppressor gene, may play a role in the pathogenesis of this disease | None |
| could function as a tumor suppressor and might be silenced by promoter hypermethylation | None |
| SPARC acts as an oncogene in transformed myelodysplastic syndrome/acute myeloid leukemia. | leukemia, |
| SPARC silencing inhibits the growth of acute myeloid leukemia transformed from myelodysplastic syndrome via induction of cell cycle arrest and apoptosis. | leukemia, |
| Secretion of SPARC by endothelial cells transformed by polyoma middle T oncogene inhibits the growth of normal endothelial cells in vitro. | None |